Bell's Palsy (Acute Idiopathic Facial Paralysis)
Investigational adjunct in acute idiopathic facial nerve palsy; no controlled trial identified, only uncontrolled series and single-case reports.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for Bell's palsy. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for Bell's palsy is investigational.
- What evidence exists?
- Tier C (investigational). No randomized controlled trial of leech therapy in Bell's palsy was identified; the reports found are uncontrolled (a Soviet-era series of 80 patients with peripheral facial nerve palsy, and single-patient Ayurvedic case reports). Spontaneous recovery is high (about 70-85%) which complicates interpretation of uncontrolled reports. Evidence-based first-line therapy is high-dose oral corticosteroids started within 72 hours of symptom onset (NNT ~10), with consideration of antivirals in severe cases; physical therapy / facial-rehabilitation exercises also help.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment (placement on the face)
- Bruising and tenderness on visible facial skin for 5 to 10 days
- Itching and irritation at bite sites
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Bite marks on the face, which usually fade over weeks to months but matter more cosmetically there
- Delayed presentation to neurology if used in place of evidence-based steroid therapy, missing the 72-hour window
- Who should not consider this
- Patients on blood thinners (anticoagulants such as warfarin, DOACs or heparin)
- Patients with hemophilia or other bleeding disorders
- Patients with anemia
- Patients considering this INSTEAD OF oral corticosteroids within the 72-hour window
- Patients with atypical features (bilateral, slowly progressive, other neurologic signs) — needs urgent neurology workup
- Patients with active herpes zoster (Ramsay Hunt syndrome) or Lyme disease (treat the cause)
- Patients with a weakened immune system
- What to ask your clinician
- Have I been seen by a neurologist or ENT promptly to confirm Bell's palsy and rule out other causes (stroke, Ramsay Hunt, Lyme)?
- Have I started oral corticosteroids within the 72-hour window?
- Has eye-protection been arranged (lubrication, taping, eye patch) to prevent corneal injury?
- What evidence supports leech therapy for Bell's palsy specifically?
- Will leeches be kept away from the eye and lid?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the cost?
- When to seek urgent care
- Sudden facial weakness with other neurologic symptoms — arm/leg weakness, speech difficulty, vision change (possible stroke — call 911)
- Bilateral facial weakness, progressive weakness over days, or rash with painful blisters in or around the ear (Ramsay Hunt)
- Severe eye pain, redness, or vision change (corneal injury from inability to close the eye)
- Spreading redness, warmth, pus, or red streaks on the face (cellulitis)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for Bell's palsy.
- High spontaneous-recovery rate (70-85%) means uncontrolled case reports cannot establish efficacy.
- Mechanism rationale (local anti-inflammation around the facial nerve) does NOT establish clinical efficacy.
- Leech therapy is NOT a substitute for early oral corticosteroids in the 72-hour window.
- Facial leech application carries cosmetic risk and proximity to eye/ear structures.
Safety cross-references
Clinical Profile
- Category
- Neurological
- ICD-10
- G51.0
- Safety tier
- Medium
Evidence Summary
Bell's palsy spontaneous recovery rates exceed 70% with early high-dose corticosteroids per AAN/AAO-HNS 2013 guidelines. No controlled clinical trial of leech therapy for Bell's palsy was identified. The clinical reports found are uncontrolled: a Soviet-era series of 80 patients with peripheral facial nerve palsy (Farber 1985, Novosibirsk, as summarised by Baskova & Isakhanyan 2004) in which leeches were reported to shorten mean hospital stay from 28.8 to 23.6 days, and single-patient Ayurvedic case reports in which leeches were one part of a multimodal regimen (e.g., Jain & Vaijwade 2024). Use is investigational, with a proposed but unproven mechanism of perineurial edema reduction at the stylomastoid foramen. Evidence grade is D. Standard care (prednisone 60 mg/day × 7-10 days, eye protection, antiviral co-therapy initiated within 72 hours) remains primary.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan do not write about Bell’s palsy specifically: they speak of peripheral facial nerve palsies in general and include facial nerve palsy among the indications for hirudotherapy[B1].
- They retell the observation by F. M. Farber (1985) of 80 patients with peripheral facial nerve palsy: in this account, the possibility of making the complex treatment more effective and of shortening the average hospital stay from 28.8 to 23.6 days is emphasized[B1].
- From this account it is not clear what the 28.8 and 23.6 days were compared against, which exact complex treatment was given together with the leeches, how the recovery of facial expression was assessed, or how long the patients were followed[B1].
- In the same retelling, the mechanism is explained by the leeches’ ability to draw blood away, which, according to this explanation, reduces swelling of the facial nerve and pressure on the nerve; it also says that hirudotherapy is particularly indicated for patients whose illness developed against a background of raised blood pressure[B1].
- Michalsen et al. do not write about facial nerve palsy or about Bell’s palsy: this condition is found neither among the indications nor among the data on effectiveness[B3].
- Baskova and Isakhanyan consider hirudotherapy relatively contraindicated where leeches could lead to cosmetic defects; Michalsen et al. advise restraint on the face for esthetic reasons and write that if the wounds are left undisturbed, the traces of the bites usually quickly shrink to hardly visible or invisible tiny marks that disappear completely within one to three weeks, whereas if wound healing is impaired by scratching or infection, the traces may remain visible for significantly longer[B1][B3].
- Among the general contraindications, Baskova and Isakhanyan name hemophilia and other hemorrhagic diatheses, anemias, low blood pressure, shock and fainting, cachexia, concurrent use of anticoagulants and alcohol; Flecken and Michalsen regard congenital or acquired hemophilia and the use of anticoagulants as an absolute contraindication[B1][B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Ramsay Hunt syndrome (herpes zoster) — antiviral therapy primary
- Suspected stroke or central lesion (image first)
- Otitis media or external ear infection
Related Conditions
Trigeminal Neuralgia (Classical / Idiopathic)
Investigational use for classical trigeminal neuralgia refractory to first-line carbamazepine; only two single-patient case reports were located in journals (see also “What the books describe”).
Chronic Rhinosinusitis
Investigational use for chronic rhinosinusitis; no clinical study of leech therapy for this condition was identified, and the rationale is mechanistic.
Cervicogenic Headache
Investigational adjunct for cervicogenic headache referred from upper cervical (C1-C3) joints; no clinical study in diagnosed cases was identified.
Cervical Radiculopathy
Investigational use for cervical radiculopathy; no verifiable published trial specific to this indication.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.